Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study).
Echemann M, Alla F, Briançon S, Juillière Y, Virion JM, Mertès PM, Villemot JP, Zannad F, Aliot E, Breton Ch, KhalifE K, Neimann JL, Allam S, Admant P, Baille N, Bellanger P, D'Hôtel R, Dambrine P, Dodet JF, Graille M, Kessler M, Rebeix G, Royer, Saulnier JP, Thisse JY, Trutt B, Vidal P, Vuillemin MCh, Delahaye, Ducimetière P, Fagnani F, Guize L; EPICAL Investigators. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine.
Echemann M, et al. Among authors: khalife k.
Eur J Heart Fail. 2002 Oct;4(5):647-54. doi: 10.1016/s1388-9842(02)00028-4.
Eur J Heart Fail. 2002.
PMID: 12413509
Free article.
Nevertheless so far, there is no published controlled study of long-term antithrombotic therapy in patients with CHF. The aim of this work was to identify the relationship between cardiovascular drug use, especially antithrombotic therapy, and survival of CHF patients in c …
Nevertheless so far, there is no published controlled study of long-term antithrombotic therapy in patients with CHF. The aim of this …